Polymorphic Forms of N-Benzylacetamide for Stable Drug Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing polymorphic forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide are unreliable and fail to consistently generate forms with desirable physicochemical properties, such as solubility and stability.
Innovation Solution
The development of three distinct polymorphic forms (A, B, and C) of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide, characterized by specific X-ray powder diffraction patterns, thermal properties, and stability under various conditions, along with a pharmaceutical composition incorporating Form B.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing methods are used to produce polymorphic forms, then production can proceed with conventional approaches, but the methods are unreliable and fail to consistently generate forms with desirable physicochemical properties
Solution Approach 1:
The patent applies parameter changes by systematically varying crystallization conditions including solvent type (e.g., ethanol, isopropanol, acetonitrile), temperature ranges (from -20°C to room temperature), pH levels, and concentration ratios to reliably produce specific polymorphic forms with desired physicochemical properties
Solution Approach 2:
The patent employs preliminary action through seed crystal addition and pre-equilibration of solutions before crystallization. By preparing solutions at specific temperatures and pH levels, then slowly cooling or evaporating under controlled conditions, the method ensures consistent formation of target polymorphs
2Stability of the object's composition
If polymorphic forms are produced to improve solubility and stability, then drug performance can be enhanced, but the processes fail to generate them consistently and reliably
Solution Approach 1:
The patent incorporates feedback mechanisms by monitoring crystallization progress through analytical methods (XRPD, DSC, HPLC) and adjusting parameters such as temperature, pH, and solvent composition in real-time to maintain consistent production of stable polymorphic forms
Solution Approach 2:
The patent applies dynamics by using controlled rate processes including gradual cooling from elevated temperatures, stepwise pH adjustment, and controlled solvent evaporation rates to dynamically guide the system toward stable polymorphic forms while ensuring reproducible results
3Adaptability or versatility
If multiple polymorphic forms are developed with different properties, then desirable physicochemical properties can be achieved, but the complexity of characterizing and controlling forms increases
Solution Approach 1:
The patent applies segmentation by dividing the crystallization process into distinct stages (nucleation, growth, maturation) and using different solvent systems for different polymorphic forms, allowing systematic characterization and control of each form's unique properties
Solution Approach 2:
The patent uses intermediary substances such as surfactants (e.g., polysorbate 80, poloxamer 188) and buffer systems to mediate the crystallization process, enabling controlled formation of specific polymorphic forms with desired properties while simplifying characterization through consistent formation conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The identified polymorphic forms exhibit improved solubility, stability, and hygroscopicity, maintaining their physical form and purity under different storage conditions, making them suitable for pharmaceutical applications.
Implementation Method 1
characterized by an X-ray powder diffraction pattern comprising peaks at approximately 6.4, 7.2, 19.3, 19.9, 21.6, 22.1, and 22.6 °2θ using Cu Kα radiation
Implementation Method 2
characterized by an endothermic event with onset between approximately 133°C and approximately 138°C as measured by DSC
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present application provides solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide, and methods of preparing and using same.